Preoperative imatinib mesylate (IM) for huge gastrointestinal stromal tumors (GIST)
نویسندگان
چکیده
منابع مشابه
Preoperative imatinib mesylate (IM) for huge gastrointestinal stromal tumors (GIST)
BACKGROUND Preoperative imatinib mesylate (IM) treatment has not yet been standardized. Here, we aim to further explore such therapy on patients with gastrointestinal stromal tumors (GIST) retrospectively. METHODS Patients experiencing preoperative IM were identified from January 2009 to February 2015. RESULTS A total of 28 GIST patients were identified. The patients received preoperative I...
متن کاملImatinib Mesylate: A Molecularly Targeted Therapy for Gastrointestinal Stromal Tumors
Although their overall incidence is uncommon, gastrointestinal stromal tumors (GIST) are the most frequently encountered mesenchymal tumors of the GI tract. Their pathology has been recently defined by the presence of KIT (transmembrane receptor tyrosine kinase). The majority of GISTs have c-kit gain-of-function mutations mainly in exon 11 (highly conserved juxtamembrane region) that eventuates...
متن کاملImatinib mesylate: a molecularly targeted therapy for gastrointestinal stromal tumors.
Although their overall incidence is uncommon, gastrointestinal stromal tumors (GIST) are the most frequently encountered mesenchymal tumors of the GI tract. Their pathology has been recently defined by the presence of KIT (transmembrane receptor tyrosine kinase). The majority of GISTs have c-kit gain-of-function mutations mainly in exon 11 (highly conserved juxtamembrane region) that eventuates...
متن کاملEvaluating and Reporting Gastrointestinal Stromal Tumors after Imatinib Mesylate Treatment
Malignant and advanced gastrointestinal stromal tumors (GIST) are currently treated with imatinib mesylate, an inhibitor of KIT and PDGFRA receptor tyrosine kinase. Pathologic evaluation of residual disease is the gold standard in these cases, as clinical and radiologic assessments of treatment response do not always correlate with the pathologic response. Phenotypic and genotypic changes may a...
متن کاملImatinib treatment for gastrointestinal stromal tumour (GIST)
Gastrointestinal stromal tumour (GIST) is the most common mesenchymal neoplasm of the gastrointestinal tract. GISTs are believed to originate from intersticial cells of Cajal (the pacemaker cells of the gastrointestinal tract) or related stem cells, and are characterized by KIT or platelet-derived growth factor receptor alpha (PDGFRA) activating mutations. The use of imatinib has revolutionized...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: World Journal of Surgical Oncology
سال: 2017
ISSN: 1477-7819
DOI: 10.1186/s12957-017-1143-2